.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,045,119

« Back to Dashboard

Details for Patent: 7,045,119

Title:Delivery of diazepam through an inhalation route
Abstract: The present invention relates to the delivery of compounds for the treatment of anxiety disorders and symptoms of such disorders through an inhalation route. Specifically, it relates to aerosols containing that are used in inhalation therapy. In a method aspect of the present invention, diazepam is administered to a patient through an inhalation route. The method comprises: a) heating a composition, comprising diazepam to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol with less than 5% of the drug degradation products. In a kit aspect of the present invention, a kit for delivering diazepam through an inhalation route is provided which comprises: a) a thin coating of a diazepam composition; and, b) a device for dispending said thin coating as a condensation aerosol
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:Mar 03, 2004
Application Number:10/792,001
Claims:1. A method of treating anxiety disorders or symptoms in a patient comprising administering a therapeutic amount of a diazepam condensation aerosol to the patient by inhalation, wherein the condensation aerosol is formed by heating a thin layer containing diazepam, on a solid support, to produce a vapor of diazepam, and condensing the vapor to form a condensation aerosol characterized by less than 10% diazepam degradation products by weight, and an MMAD of less than 5 microns.

2. The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

3. The method according to claim 1, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second.

4. The method according to claim 1, wherein the therapeutic amount of the diazepam condensation aerosol comprises between 0.2 mg and 20 mg of diazepam delivered in a single inspiration.

5. The method according to claim 1, wherein peak plasma diazepam concentration is reached in less than 0.1 hours.

6. The method according to claim 1, wherein at least 50% by weight of the condensation aerosol is amorphous in form.

7. A method of administering a diazepam condensation aerosol to a patient comprising administering the diazepam condensation aerosol to the patient by inhalation, wherein the diazepam condensation aerosol is formed by heating a thin layer containing diazepam, on a solid support, to produce a vapor of diazepam, and condensing the vapor to form a condensation aerosol characterized by less than 10% diazepam degradation products by weight, and an MMAD of less than 5 microns.

8. A kit for delivering a diazepam condensation aerosol comprising: a. a thin layer containing diazepam, on a solid support, and b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of diazepam, and condensing the vapor to form a condensation aerosol characterized by less than 10% diazepam degradation products by weight, and an MMAD of less than 5 microns.

9. The kit according to claim 8, wherein the device comprises: a. a flow through enclosure containing the solid support, b. a power source that can be activated to heat the solid support, and c. at least one portal through which air can be drawn by inhalation, wherein activation of the power source is effective to produce a vapor of diazepam, and drawing air through the enclosure is effective to condense the vapor to form the condensation aerosol.

10. The kit according to claim 9, wherein the heat for heating the solid support is generated by an exothermic chemical reaction.

11. The kit according to claim 10, wherein the exothermic chemical reaction is oxidation of combustible materials.

12. The kit according to claim 9, wherein the heat for heating the solid support is generated by passage of current through an electrical resistance element.

13. The kit according to claim 9, wherein the solid support has a surface area dimensioned to accommodate a therapeutic dose of diazepam.

14. The kit according to claim 8, wherein peak plasma diazepam concentration is reached in less than 0.1 hours.

15. The kit according to claim 8, further including instructions for use.

16. The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

17. The method according to claim 2, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

18. The method according to claim 1, wherein the thin layer has a thickness between 1.3 and 5.1 microns.

19. The kit according to claim 8, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

20. The kit according to claim 8, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

21. The kit according to claim 23, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

22. The kit according to claim 8, wherein the thin layer has a thickness between 1.3 and 5.1 microns.

23. The kit according to claim 9, wherein the solid support has a surface to mass ratio of greater than 1 cm.sup.2 per gram.

24. The kit according to claim 9, wherein the solid support has a surface to volume ratio of greater than 100 per meter.

25. The kit according to claim 9, wherein the solid support is a metal foil.

26. The kit according to claim 25, wherein the metal foil has a thickness of less than 0.25 mm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc